Navigation Links
WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat(TM) Antibody Collaboration
Date:9/4/2012

SHANGHAI and PALO ALTO, Calif., Sept. 4, 2012 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, and Open Monoclonal Technology, Inc. (OMT), an innovator in novel transgenic animals for development of human therapeutic antibodies, today announced that they have entered into an agreement to use OMT's OmniRat™ to develop therapeutic antibody candidates for commercialization by WuXi's global customers.

This transaction advances WuXi's goal of working with skilled partners to enhance the company's platform of technologies and capabilities to serve its customers better.

The OmniRat™ technology generates fully human antibodies with great specificity, affinity and manufacturability. It eliminates time-consuming humanization of traditional mouse-derived antibodies and the need for optimization of lead candidates using phage display technology.

"OMT's OmniRat™ technology allows WuXi to expand its service offerings in discovery of fully human antibodies," said Edward Hu, Chief Operating Officer and Chief Financial Officer of WuXi PharmaTech. "Providing discovery, development and manufacturing services for novel therapeutic antibodies represents an important new global business initiative for WuXi. We are investing heavily in building our capabilities and capacity in biologics services, which we expect to be a key driver of revenue growth for our company in the coming years."

Dr. Roland Buelow, founder and CEO of OMT, continued, "The collaboration with WuXi further advances OMT's efforts to deploy its human antibody platform globally. Under the collaboration, OMT can leverage WuXi's expertise and capacity to create novel therapeutic candidates for its biopharmaceutical customers and apply OMT's technology to an ever-broadening base of drug candidates."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners shorten the cycle and lower the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

About Open Monoclonal Technology, Inc. - naturally optimized human antibodies™

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for development of human therapeutic antibodies. OMT has developed OmniRat™, the first fully human monoclonal antibody platform based on transgenic rats. OmniRat is based on an improved understanding of B cell development and a novel approach to inactivation of endogenous antibody expression. These transgenic animals make antibodies as efficiently as wild type animals. OmniRat is a new and proprietary technology with unrestricted development options for fully human monoclonal antibodies across all targets and indications worldwide.

For more information

Please visit www.wuxiapptec.com, www.omtinc.net or contact:

Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech (Cayman) Inc.
Phone:  +1-201-585-2048
E-mail:  Ron_Aldridge@wuxiapptec.com

Brian Lundstrom
Chief Business Officer
Open Monoclonal Technology, Inc.
Phone:  +1-510-220-5599
E-mail: bl@omtinc.net

 

 


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
2. Industry Leading Pharmaceutical News Website in-Pharmatechnologist.com Refocused and Relaunched
3. WuXi PharmaTech Announces First-Quarter 2012 Results
4. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
5. WuXi PharmaTech Announces Second-Quarter 2012 Results
6. WuXi PharmaTech Receives GLP Certificate from SFDA for Suzhou Toxicology Facility
7. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
8. VLST Corporation Announces In-licensing Agreement with Pfizer for Anti-CD40 Monoclonal Antibody
9. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
10. Fujitsu to Showcase Radiation-Hardened RFID Using FRAM Technology at Interphex 2012 in New York City, Booth #2430
11. SolutionStart Corp. Announces John Karagiannis as Vice President of Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):